Wednesday, March 13, 2024 9:03:48 AM
Fred indicated that they would provide a patient start/slots reserved number during the next earnings call. Assuming they report at the beginning of May, so the numbers would be thru end of April (75 days), how many patient enrollments does everyone predict? They had 20 in the first 10 days. My projection (pure guess) is 185 which is 15/week (or roughly 1/ATC every other week). Since there is a 34 day lag and the average price is about 500k (adjusted for Proleukin and Medicare/Medicaid payer mix), this would lead to Q2 revenue of about $92M. For comparison, analysts have an average Q2 revenue of 27.5M (or 55 patients) with a high of $60M (or 120 patients). This is why I am playing for an upside surprise on Q1, Q2 and Q3 ERs as I think the street is way behind the curve (and I think my numbers may be conservative). Thoughts and predictions?
Recent IOVA News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 • GlobeNewswire Inc. • 06/01/2026 11:30:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/22/2026 09:15:00 PM
- Iovance Biotherapeutics to Present at Upcoming Conference • GlobeNewswire Inc. • 05/21/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:18:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:16:23 PM
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 11:05:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/01/2026 09:00:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:05:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 09:01:20 PM
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
